2016 HCPCS Q0180
Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen

  • Added on Wednesday, April 01, 1998
  • Status changed on Wednesday, April 01, 1998 to: No maintenance for this code
  • BETOS Classification: Chemotherapy
  • Medicare coverage status: Special coverage instructions apply

  Q0178    Q0181